A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors
about
Signaling Pathways in Thyroid Cancer and Their Therapeutic ImplicationsPreclinical Data on Efficacy of 10 Drug-Radiation Combinations: Evaluations, Concerns, and RecommendationsSunitinib: the antiangiogenic effects and beyondEvolving Therapies and FAK Inhibitors for the Treatment of CancerA dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumoursClinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials.Regorafenib: from bench to bedside in colorectal cancer.The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors.5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma.Targeting angiogenesis in metastatic breast cancerSimultaneous delivery of cytotoxic and biologic therapeutics using nanophotoactivatable liposomes enhances treatment efficacy in a mouse model of pancreatic cancer.The potential of sunitinib as a therapy in ovarian cancer.Drug interactions with sunitinib.Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?Recent aspects of sunitinib therapy in patients with metastatic clear-cell renal cell carcinoma: a systematic review of the literature.Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy.Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor mo
P2860
Q26764899-4C50ADD7-1442-4C12-9DE6-AE12CF97973BQ26767798-66FC9B09-A054-433B-A420-D0CCED2A1835Q28066499-FDFA8A76-E401-4110-BE10-99AEC4F9AC53Q28972291-96CD2D06-93D1-4C46-A300-54871DF842C2Q33274982-EBCA8EEC-E2E3-422F-91C2-04A0F942F957Q33633431-A338DAE4-5013-4267-9501-5D8C4964B258Q34343524-D5FBC59F-82B7-4DEA-B5B0-E7A50E8CD664Q34725749-D6BD2F46-B979-4956-8B89-F9D0BC366D59Q36084341-2C4C2760-D987-4631-8FF6-43AE60280360Q36182795-89C634AA-F518-474A-89CA-976DCCBC6A77Q36505652-E00D8DCD-BC8D-4508-94D1-67EBAE1AC973Q38144166-00F9EC14-8227-412F-A73D-4A3C7848EE10Q38176853-8C8ED936-2ED9-4A95-A044-6BB0D3F91921Q38322346-8FC3EC26-6E70-422A-8C79-B501AE605649Q38334611-F37E4AF8-40D7-4122-91F9-45F2694FCA66Q39995898-E628325A-0C2F-42A4-883B-9C266F75769DQ40126912-673DD97B-15D7-423A-88BA-0CA8A213E3F4Q43841175-6E3A4CEB-733A-4409-8823-B03F099D104EQ49886531-FBAADA8B-A187-4321-BC5B-2168B8F202A0Q54526385-C6F9C0E7-7E90-4196-B2D2-791764841C82
P2860
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors
@ast
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors
@en
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors
@nl
type
label
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors
@ast
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors
@en
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors
@nl
prefLabel
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors
@ast
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors
@en
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors
@nl
P2093
P2860
P356
P1476
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors
@en
P2093
Akintunde Bello
Christopher J Sweeney
Claire F Verschraegen
E Gabriela Chiorean
Fa Chyi Lee
Howard A Burris
Katherine F Liau
Lesley Tye
Melanie Royce
Richard Chao
P2860
P304
P356
10.1200/JCO.2009.26.9696
P407
P577
2010-09-13T00:00:00Z